Management of Testicular Germ Cell Tumors

被引:0
作者
Wee, Christopher E. [1 ]
Gilligan, Timothy D. [1 ]
机构
[1] Cleveland Clin, Dept Hematol & Med Oncol, Taussig Canc Inst, 9500 Euclid Ave,CA-60, Cleveland, OH 44195 USA
关键词
Testicular germ cell tumors; testis cancer; LYMPH-NODE DISSECTION; POSTCHEMOTHERAPY RESIDUAL MASSES; CISPLATIN-BASED CHEMOTHERAPY; ETOPOSIDE PLUS CISPLATIN; HIGH-DOSE CHEMOTHERAPY; RANDOMIZED-TRIAL; CANCER INCIDENCE; ADJUVANT CHEMOTHERAPY; ADVANCED SEMINOMA; STAGE IIA;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Over the past half century, advancements in treat-ment have led to cures in an overwhelming majority of patients with testicular germ cell tumors. Astute clinical decision-making, informed by the abundant data from published clinical trials, is essential for achieving a cure whenever possible and minimizing the toxicity of treatment. Important remaining challenges include reducing the risk of secondary malignancies and other late effects of chemotherapy and radiation therapy, and developing curative treatments for patients with cancer that is refractory to current therapies. This article reviews the current treatment landscape and highlights recent discoveries in diagnosis and staging, emerging biomarkers for disease, and treatment for relapsed/refractory disease. Treatment algorithms for testis cancer are complex and clinicians should apply them carefully, not only to optimize short-term, disease-related outcomes, but also to maximize long-term survival and quality of life.
引用
收藏
页码:179 / 188
页数:10
相关论文
共 96 条
  • [1] Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206
    Adra, N.
    Einhorn, L. H.
    Althouse, S. K.
    Ammakkanavar, N. R.
    Musapatika, D.
    Albany, C.
    Vaughn, D.
    Hanna, N. H.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (01) : 209 - 214
  • [2] High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience
    Adra, Nabil
    Abonour, Rafat
    Althouse, Sandra K.
    Albany, Costantine
    Hanna, Nasser H.
    Einhorn, Lawrence H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (10) : 1096 - +
  • [3] Al-Obaidy Khaleel I, 2022, Surg Pathol Clin, V15, P745, DOI 10.1016/j.path.2022.07.010
  • [4] Management of Residual Mass in Germ Cell Tumors After Chemotherapy
    Albany, Costantine
    Kesler, Kenneth
    Cary, Clint
    [J]. CURRENT ONCOLOGY REPORTS, 2019, 21 (01)
  • [5] Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German testicular cancer study group
    Albers, Peter
    Siener, Roswitha
    Krege, Susanne
    Schmelz, Hans-Uwe
    Dieckmann, Klaus-Peter
    Heidenreich, Axel
    Kwasny, Peter
    Pechoel, Maik
    Lehmann, Jan
    Kliesch, Sabine
    Koehrmann, Kai-Uwe
    Fimmers, Rolf
    Weissbach, Lothar
    Loy, Volker
    Wittekind, Christian
    Hartmann, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (18) : 2966 - 2972
  • [6] The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
    Albers, Peter
    Hiester, Andreas
    Siemer, Robert Grosse
    Lusch, Achim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [7] Clinical stage II seminoma: management options
    Alsyouf, Muhannad
    Daneshmand, Siamak
    [J]. WORLD JOURNAL OF UROLOGY, 2022, 40 (02) : 343 - 348
  • [8] [Anonymous], 1997, J Clin Oncol, V15, P594
  • [9] [Anonymous], SEER CANC STAT FACTS
  • [10] [Anonymous], 2022, COMPL PAT RECR INT T